Yahoo
Shanghai - Delayed Quote CNY

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (603707.SS)

8.20 +0.03 (+0.37%)
At close: 3:00:02 PM GMT+8
View in AlphaSpace Currency in CNY All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
4,070,761.69
3,990,678.04
3,923,585.84
3,931,387.28
3,712,720.46
Cost of Revenue
2,604,398.66
2,418,108.67
2,228,370.21
2,028,720.81
1,767,997.71
Gross Profit
1,466,363.03
1,572,569.36
1,695,215.63
1,902,666.47
1,944,722.75
Operating Expense
1,015,113.17
991,202.32
780,014.19
939,584.25
912,050.45
Operating Income
451,249.86
581,367.05
915,201.44
963,082.22
1,032,672.30
Net Non Operating Interest Income Expense
-42,415.15
-39,156.91
-58,841.64
-54,682.21
-26,274.48
Pretax Income
532,532.60
699,416.37
992,033.75
-294,758.51
1,185,369.26
Tax Provision
107,308.08
117,905.54
165,934.74
-105,311.96
98,850.19
Net Income Common Stockholders
425,216.56
581,536.15
826,144.87
-189,445.79
1,090,833.20
Basic EPS
0.26
0.36
0.51
-0.12
0.67
Diluted EPS
0.26
0.36
0.50
-0.12
0.67
Basic Average Shares
1,627,476.68
1,615,378.21
1,619,891.90
1,578,714.92
1,628,109.26
Diluted Average Shares
1,627,476.68
1,571,719.34
1,652,289.74
1,578,714.92
1,628,109.26
Total Operating Income as Reported
532,440.76
700,868.95
994,328.32
-294,708.87
1,173,551.94
Rent Expense Supplemental
--
13,761.02
5,846.55
6,762.21
3,915.60
Total Expenses
3,619,511.83
3,409,310.99
3,008,384.40
2,968,305.06
2,680,048.16
Net Income from Continuing & Discontinued Operation
425,216.56
581,536.15
826,144.87
-189,445.79
1,090,833.20
Normalized Income
279,846.09
402,364.76
755,021.15
609,620.62
1,104,550.86
Interest Income
33,112.81
18,646.43
19,194.48
27,983.43
33,393.12
Interest Expense
56,266.08
55,249.52
75,664.28
81,045.09
57,847
Net Interest Income
-42,415.15
-39,156.91
-58,841.64
-54,682.21
-26,274.48
EBIT
588,798.68
754,665.89
1,067,698.03
-213,713.42
1,243,216.26
EBITDA
588,798.68
997,650.67
1,242,551.98
-59,653.91
1,382,748.63
Reconciled Cost of Revenue
2,604,398.66
2,418,108.67
2,228,370.21
2,028,720.81
1,767,997.71
Reconciled Depreciation
216,838.99
242,984.78
174,853.95
154,059.51
139,532.37
Net Income from Continuing Operation Net Minority Interest
425,216.56
581,536.15
826,144.87
-189,445.79
1,090,833.20
Total Unusual Items Excluding Goodwill
182,055.62
215,499.70
85,410.02
-1,243,261.61
-14,965.67
Total Unusual Items
182,055.62
215,499.70
85,410.02
-1,243,261.61
-14,965.67
Normalized EBITDA
406,743.06
782,150.97
1,157,141.96
1,183,607.70
1,397,714.30
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
36,685.15
36,328.30
14,286.30
-444,195.19
-1,248.02
12/31/2022 - 7/19/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: